全文获取类型
收费全文 | 6836篇 |
免费 | 438篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 74篇 |
儿科学 | 225篇 |
妇产科学 | 285篇 |
基础医学 | 791篇 |
口腔科学 | 62篇 |
临床医学 | 764篇 |
内科学 | 1294篇 |
皮肤病学 | 222篇 |
神经病学 | 751篇 |
特种医学 | 155篇 |
外科学 | 740篇 |
综合类 | 59篇 |
一般理论 | 16篇 |
预防医学 | 853篇 |
眼科学 | 106篇 |
药学 | 408篇 |
中国医学 | 3篇 |
肿瘤学 | 487篇 |
出版年
2024年 | 9篇 |
2023年 | 102篇 |
2022年 | 114篇 |
2021年 | 256篇 |
2020年 | 179篇 |
2019年 | 249篇 |
2018年 | 251篇 |
2017年 | 175篇 |
2016年 | 167篇 |
2015年 | 192篇 |
2014年 | 265篇 |
2013年 | 413篇 |
2012年 | 545篇 |
2011年 | 569篇 |
2010年 | 288篇 |
2009年 | 269篇 |
2008年 | 470篇 |
2007年 | 443篇 |
2006年 | 445篇 |
2005年 | 412篇 |
2004年 | 347篇 |
2003年 | 285篇 |
2002年 | 284篇 |
2001年 | 57篇 |
2000年 | 43篇 |
1999年 | 42篇 |
1998年 | 43篇 |
1997年 | 42篇 |
1996年 | 32篇 |
1995年 | 30篇 |
1994年 | 28篇 |
1993年 | 21篇 |
1992年 | 24篇 |
1991年 | 29篇 |
1990年 | 11篇 |
1989年 | 19篇 |
1988年 | 17篇 |
1987年 | 14篇 |
1986年 | 5篇 |
1985年 | 10篇 |
1984年 | 11篇 |
1983年 | 10篇 |
1982年 | 14篇 |
1981年 | 8篇 |
1979年 | 6篇 |
1977年 | 5篇 |
1975年 | 7篇 |
1972年 | 5篇 |
1971年 | 4篇 |
1968年 | 4篇 |
排序方式: 共有7295条查询结果,搜索用时 0 毫秒
91.
C. Paul Morris Holly Evans Sasha E. Larsen Edward Mitre 《Clinical microbiology reviews》2013,26(3):381-421
SUMMARY
Filarial worms cause highly morbid diseases such as elephantiasis and river blindness. Since the 1940s, researchers have conducted vaccine trials in 27 different animal models of filariasis. Although no vaccine trial in a permissive model of filariasis has provided sterilizing immunity, great strides have been made toward developing vaccines that could block transmission, decrease pathological sequelae, or decrease susceptibility to infection. In this review, we have organized, to the best of our ability, all published filaria vaccine trials and reviewed them in the context of the animal models used. Additionally, we provide information on the life cycle, disease phenotype, concomitant immunity, and natural immunity during primary and secondary infections for 24 different filaria models. 相似文献92.
Hongzhi Wang Emily W. Baker Abhyuday Mandal Ramana M. Pidaparti Franklin D. West Holly A. Kinder 《中国神经再生研究》2021,16(2):338
Traumatic brain injury(TBI) at a young age can lead to the development of long-term functional impairments. Severity of injury is well demonstrated to have a strong influence on the extent of functional impairments; however, identification of specific magnetic resonance imaging(MRI) biomarkers that are most reflective of injury severity and functional prognosis remain elusive. Therefore, the objective of this study was to utilize advanced statistical approaches to identify clinically relevant MRI biomarkers and predict functional outcomes using MRI metrics in a translational large animal piglet TBI model. TBI was induced via controlled cortical impact and multiparametric MRI was performed at 24 hours and 12 weeks post-TBI using T1-weighted, T2-weighted, T2-weighted fluid attenuated inversion recovery, diffusion-weighted imaging, and diffusion tensor imaging. Changes in spatiotemporal gait parameters were also assessed using an automated gait mat at 24 hours and 12 weeks post-TBI. Principal component analysis was performed to determine the MRI metrics and spatiotemporal gait parameters that explain the largest sources of variation within the datasets. We found that linear combinations of lesion size and midline shift acquired using T2-weighted imaging explained most of the variability of the data at both 24 hours and 12 weeks post-TBI. In addition, linear combinations of velocity, cadence, and stride length were found to explain most of the gait data variability at 24 hours and 12 weeks post-TBI. Linear regression analysis was performed to determine if MRI metrics are predictive of changes in gait. We found that both lesion size and midline shift are significantly correlated with decreases in stride and step length. These results from this study provide an important first step at identifying relevant MRI and functional biomarkers that are predictive of functional outcomes in a clinically relevant piglet TBI model. This study was approved by the University of Georgia Institutional Animal Care and Use Committee(AUP: A2015 11-001) on December 22, 2015. 相似文献
93.
Shamriz Oded Kumar Deepak Shim Jenny Briones Michael Quarmyne Maa-Ohui Chonat Satheesh Lucas Laura Edington Holly White Michael H. Mahajan Advay Park Sunita Chandrakasan Shanmuganathan 《Journal of clinical immunology》2021,41(7):1582-1596
Journal of Clinical Immunology - T cell-Epstein-Barr virus–associated hemophagocytic lymphohistiocytosis (T cell-EBV-HLH) is prevalent in East Asia and has poor prognosis. Understanding of... 相似文献
94.
Mari E. Tanaka Holly R. Brideau Thomas J. An Theresa C. McLoud Brent P. Little Hillary R. Kelly 《Current problems in diagnostic radiology》2021,50(3):351-355
PurposeThis study aimed to assess the efficacy of a virtual information session hosted by a diagnostic radiology residency program at addressing applicant concerns about the 2020-2021 interview cycle and highlighting key aspects of the residency program.MethodsParticipants were recruited to attend the virtual information session over a 2-week period via social media and communication with medical school radiology interest groups. Attendees were able to submit questions or topics of interest prior to the session. The virtual information session was hosted by trainees and faculty from a radiology residency. Data regarding the demographics of the attendees and the efficacy of the session were obtained through interactive live polling during the virtual session and a voluntary anonymous postsession survey.ResultsA total of 171 attendees participated in the virtual information session. Of the attendees, 42% learned about the session from Twitter and 72% were fourth-year medical students applying for residency. Among topics addressed during the session, attendees indicated that they were most interested in learning about “Application strategies during COVID-19” during an in-session poll. On the post-session survey, 96% of attendees reported being more knowledgeable about the residency program culture and the breadth of research and educational opportunities.ConclusionGiven the virtual nature of the 2020-2021 residency application cycle, utilization of web-based platforms for recruitment will be essential. Virtual information sessions can be effective at providing insight into aspects of a residency program that are typically gained during the in-person interview experience. 相似文献
95.
Angela Fagerlin Michael Pignone Purva Abhyankar Nananda Col Deb Feldman-Stewart Teresa Gavaruzzi Jennifer Kryworuchko Carrie A Levin Arwen H Pieterse Valerie Reyna Anne Stiggelbout Laura D Scherer Celia Wills Holly O Witteman 《BMC medical informatics and decision making》2013,13(Z2):S8
Background
Consensus guidelines have recommended that decision aids include a process for helping patients clarify their values. We sought to examine the theoretical and empirical evidence related to the use of values clarification methods in patient decision aids.Methods
Building on the International Patient Decision Aid Standards (IPDAS) Collaboration’s 2005 review of values clarification methods in decision aids, we convened a multi-disciplinary expert group to examine key definitions, decision-making process theories, and empirical evidence about the effects of values clarification methods in decision aids. To summarize the current state of theory and evidence about the role of values clarification methods in decision aids, we undertook a process of evidence review and summary.Results
Values clarification methods (VCMs) are best defined as methods to help patients think about the desirability of options or attributes of options within a specific decision context, in order to identify which option he/she prefers. Several decision making process theories were identified that can inform the design of values clarification methods, but no single “best” practice for how such methods should be constructed was determined. Our evidence review found that existing VCMs were used for a variety of different decisions, rarely referenced underlying theory for their design, but generally were well described in regard to their development process. Listing the pros and cons of a decision was the most common method used. The 13 trials that compared decision support with or without VCMs reached mixed results: some found that VCMs improved some decision-making processes, while others found no effect.Conclusions
Values clarification methods may improve decision-making processes and potentially more distal outcomes. However, the small number of evaluations of VCMs and, where evaluations exist, the heterogeneity in outcome measures makes it difficult to determine their overall effectiveness or the specific characteristics that increase effectiveness.96.
97.
The minimum important difference for the International consultation on incontinence questionnaire—Urinary incontinence short form in women with stress urinary incontinence 下载免费PDF全文
98.
Linda?BrubakerEmail author Heather?J.?Litman Hae-Young?Kim Philippe?Zimmern Keisha?Dyer John?W.?Kusek Holly?E.?Richter Anne?Stoddard for the Urinary Incontinence Treatment Network 《International urogynecology journal》2015,26(8):1155-1159
Introduction and hypothesis
Missing data is frequently observed in clinical trials; high rates of missing data may jeopardize trial outcome validity.Purpose
We determined the rates of missing data over time, by type of data collected and compared demographic and clinical factors associated with missing data among women who participated in two large randomized clinical trials of surgery for stress urinary incontinence, the Stress Incontinence Surgical Treatment Efficacy Trial (SISTEr) and the Trial of Midurethral Sling (TOMUS).Methods
The proportions of subjects who attended and missed each follow-up visit were calculated. The chi-squared test, Fisher’s exact test and t test were used to compare women with and without missing data, as well as the completeness of the data for each component of the composite primary outcome.Results
Data completeness for the primary outcome computation in the TOMUS trial (62.3 %) was nearly double that in the SISTEr trial (35.7 %). The follow-up visit attendance rate decreased over time. A higher proportion of subjects attended all follow-up visits in the TOMUS trial and overall there were fewer missing data for the period that included the primary outcome assessment at 12 months. The highest levels of complete data for the composite outcome variables were for the symptoms questionnaire (SISTEr 100 %, TOMUS 99.8 %) and the urinary stress test (SISTEr 96.1 %, TOMUS 96.7 %). In both studies, the pad test was associated with the lowest levels of complete data (SISTEr 85.1 %, TOMUS 88.3 %) and approximately one in ten subjects had incomplete voiding diaries at the time of primary outcome assessment. Generally, in both studies, a higher proportion of younger subjects had missing data. This analysis lacked a patient perspective as to the reasons for missing data that could have provided additional information on subject burden, motivations for adherence and study design. In addition, we were unable to compare the effects of the different primary outcome assessment time-points in an identically designed trial.Conclusions
Missing visits and data increased with time. Questionnaire data and physical outcome data (urinary stress test) that could be assessed during a visit were least prone to missing data, whereas data for variables that required subject effort while away from the research team (pad test, voiding diary) were more likely to be missing. Older subjects were more likely to provide complete data.99.
Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults 总被引:5,自引:0,他引:5
STUDY OBJECTIVE: To determine the steady-state, extracellular, and intracellular pulmonary disposition of moxifloxacin (MXF), levofloxacin (LEVO), and azithromycin (AZI) relative to that of the plasma over a 24-h dosing interval. DESIGN: Randomized, multicenter, open-label investigation. PATIENTS: Forty-seven older adults (mean [+/- SD] age, 62 +/- 13 years) undergoing diagnostic bronchoscopy. INTERVENTIONS: Oral administration of MXF, 400 mg, LEVO, 500 mg daily for five doses, or AZI, 500 mg for one dose, then 250 mg daily for four doses. BAL and venipuncture were completed at 4, 8, 12, or 24 h following the administration of the last dose. MEASUREMENTS AND RESULTS: Steady-state MXF, LEVO, and AZI concentrations were determined in the plasma, epithelial lining fluid (ELF), and alveolar macrophages (AMs). The concentrations of all three agents were greatest in the AMs followed by the ELF compared to the plasma. Plasma concentrations were similar to those previously reported with these agents. The mean ELF concentrations at 4, 8, 12, and 24 h were as follows: MXF, 11.7 +/- 11.9, 7.8 +/- 5.1, 10.5 +/- 3.7, and 5.7 +/- 6.3 micro g/mL, respectively; LEVO, 15.2 +/- 4.5, 10.2 +/- 6.7, 6.9 +/- 4.4, and 2.9 +/- 1.7 micro g/mL, respectively; and AZI, 0.6 +/- 0.4, 0.7 +/- 0.4, 0.9 +/- 0.5, and 0.9 +/- 0.7 micro g/mL, respectively. The AM concentrations at 4, 8, 12, and 24 h were as follows: MXF, 47.7 +/- 47.6, 123.3 +/- 126.4, 26.2 +/- 19.4, and 32.8 +/- 16.5 micro g/mL, respectively; LEVO, 28.5 +/- 30.2, 26.1 +/- 15.7, 28.3 +/- 12.6, and 8.2 +/- 6.1 micro g/mL, respectively; and AZI, 71.8 +/- 50.1, 73.8 +/- 75.3, 155.9 +/- 81.3, and 205.2 +/- 256.3 micro g/mL, respectively. CONCLUSIONS: The intrapulmonary concentrations of MXF, LEV, and AZI were superior to those obtained in the plasma. The AM concentrations of all agents studied were more than adequate relative to the minimum concentration required to inhibit 90% of the organism population (MIC(90)) of the common intracellular pathogens (< 1 micro g/mL). These data indicate that attainable extracellular concentrations of AZI are insufficient to reliably eradicate Streptococcus pneumoniae, based on the agent's current minimum inhibitory concentration profile, whereas the mean concentrations of MXF and LEVO in the ELF exceed the MIC(90) of the S pneumoniae population. Moreover, MXF concentrations exceeded the S pneumoniae susceptibility breakpoint (1.0 micro g/mL) at all time points, while 2 of 15 concentrations (13%) failed to maintain LEVO concentrations above the breakpoint (2.0 micro g/mL) throughout the dosing interval. 相似文献
100.